Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.60.

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $11.00 to $2.00 in a report on Tuesday, November 5th. TD Cowen reduced their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, October 21st. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, November 5th. Finally, HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $0.95 on Tuesday. The firm has a fifty day moving average of $1.21 and a two-hundred day moving average of $4.01. The stock has a market capitalization of $43.32 million, a price-to-earnings ratio of -0.52 and a beta of 1.40. Verrica Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $11.41. The company has a debt-to-equity ratio of 29.58, a quick ratio of 1.22 and a current ratio of 1.34.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The business had revenue of ($1.78) million for the quarter, compared to the consensus estimate of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. As a group, equities research analysts predict that Verrica Pharmaceuticals will post -1.42 EPS for the current year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC raised its holdings in shares of Verrica Pharmaceuticals by 404.6% in the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after purchasing an additional 25,130 shares during the period. Quest Partners LLC bought a new stake in shares of Verrica Pharmaceuticals in the 2nd quarter valued at about $50,000. Key Financial Inc bought a new stake in shares of Verrica Pharmaceuticals in the 2nd quarter valued at about $69,000. Sanctuary Advisors LLC bought a new stake in shares of Verrica Pharmaceuticals in the 3rd quarter valued at about $87,000. Finally, Verition Fund Management LLC bought a new stake in shares of Verrica Pharmaceuticals in the 3rd quarter valued at about $89,000. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.